(Reuters) -US Pfizer Drug (Pfe) Beating Wall Street estimates for a fourth-quarter profit on Tuesday, with the help of the strong sales of his heart disease drug and a reduction less than the fear in context vaccine sales.
On a customized basis, the company won the 63 cents per share for the three months ending December 31, compared to the analyst's estimate of an average of 47 cents per share, according to data compiled by LSEG.
Pfizer faces the pressures of investors to show that his recent acquisitions and investments can bring in earnings.
After the tremendous success of its Covid-19 products during the pandemic, the drug maker has struggled to convince shareholders that it can compensate for the potential revenue loss of some best-selling treatments that are expected to get off a patent soon .
The company's shares fell nearly 8% last year, and were up about 2% in hours before -market following the results. They trade at less than half their value at the peak of the Pandemic Covid-19.
Total revenue came in at $ 17.76 billion for the fourth quarter, compared to estimates of $ 17.36 billion, according to data compiled by LSEG.
.